Skip to content
Clinical Trials – home
Research site

Ospedale P. Pederzoli Casa Di Cura Privata S.p.A.

Italy Via Monte Baldo 24, 37019 Peschiera Del Garda, Italy

  • 21 trials recruiting
  • Non-small cell lung cancer · Non-small cell lung cancer metastatic · Small cell lung cancer extensive stage
  • Adult patients

About Specializations

Ospedale P. Pederzoli Casa Di Cura Privata S.p.A. in Peschiera Del Garda, Italy specialises in clinical trials of conditions such as Non-small cell lung cancer, Non-small cell lung cancer metastatic, Small cell lung cancer extensive stage, Non-small cell lung cancer stage IV, and other specialisations. This site conducts important research.

Main research areas of the site

Immunotherapy Advances in Metastatic NSCLC

At Ospedale P. Pederzoli Casa Di Cura Privata S.p.A. researchers are focusing on metastatic non‑small cell lung cancer using modern immunotherapy approaches to improve patient outcomes.

  • Pembrolizumab‑based treatment regimens
  • Evaluation of PD‑L1 expression as a predictive biomarker
  • Comparison of overall survival between combination therapies

These studies aim to determine whether adding new agents to pembrolizumab can extend survival and delay disease progression for patients with advanced lung cancer.

Combination Chemotherapy and Targeted Antibody Trials

The site is testing innovative pairings of chemotherapy with emerging antibodies, such as ivonescimab, to treat metastatic squamous non‑small cell lung cancer.

  • Ivonescimab combined with carboplatin and paclitaxel
  • Alternative regimen using nab‑paclitaxel
  • Assessment of safety, tolerability, and efficacy

The goal is to identify combination strategies that provide better overall survival compared with standard chemotherapy alone.

Antibody‑Drug Conjugate Research with Sacituzumab Govitecan

A separate line of investigation pairs sacituzumab govitecan with pembrolizumab to explore synergistic effects in patients with high PD‑L1 expression.

  • Pembrolizumab plus sacituzumab govitecan versus pembrolizumab alone
  • Progression‑free survival measured by RECIST 1.1
  • Overall survival outcomes in metastatic disease

This research seeks to determine whether the antibody‑drug conjugate can enhance treatment durability and extend life expectancy for those with advanced lung cancer.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Via Monte Baldo 2437019 Peschiera Del GardaItaly
Recruiting now
21 trials
Conditions studied
21

More sites in Peschiera Del GardaItaly

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

38 clinical trials

Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BioNTech SE
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Unicancer
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BNT327
  • Sponsor:BioNTech SE
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB
Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Amgen Inc.
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:F. Hoffmann-La Roche AG
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.